The estimated Net Worth of Mary Teresa Shoemaker is at least $50.7 Tysiąc dollars as of 16 February 2021. Mary Shoemaker owns over 13,000 units of Onconova Therapeutics Inc stock worth over $50,735 and over the last 4 years Mary sold ONTX stock worth over $0.
Mary has made over 2 trades of the Onconova Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Mary bought 13,000 units of ONTX stock worth $13,000 on 16 February 2021.
The largest trade Mary's ever made was buying 37,735 units of Onconova Therapeutics Inc stock on 25 November 2020 worth over $10,188. On average, Mary trades about 8,456 units every 14 days since 2020. As of 16 February 2021 Mary still owns at least 50,735 units of Onconova Therapeutics Inc stock.
You can see the complete history of Mary Shoemaker stock trades at the bottom of the page.
Mary's mailing address filed with the SEC is C/O ONCONOVA THERAPEUTICS, INC, 12 PENNS TRAIL, NEWTOWN, PA, 18940.
Over the last 12 years, insiders at Onconova Therapeutics Inc have traded over $1,631,795 worth of Onconova Therapeutics Inc stock and bought 27,892,613 units worth $51,994,589 . The most active insiders traders include Capital, Llc Armistice Capi..., Capital Management, Llc 683 oraz Capital Partners L P Tyndall. On average, Onconova Therapeutics Inc executives and independent directors trade stock every 40 days with the average trade being worth of $294,478. The most recent stock trade was executed by Mark Patrick Guerin on 13 March 2024, trading 8,666 units of ONTX stock currently worth $8,666.
onconova therapeutics, inc. (nasdaq: ontx) is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. using a proprietary chemistry platform, onconova has created an extensive library of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. onconova has three product candidates in clinical trials and six active pre-clinical programs. onconova seeks to develop products that improve the outcome for cancer patients by directly addressing the disease, its recurrence, and the burden of side-effects associated with current methods of treatment.
Onconova Therapeutics Inc executives and other stock owners filed with the SEC include: